[1]

ZHONG Xinru, YANG Deying, GUAN Tangming, CHEN Ju, JIANG Dongbo. Research Progress in Adverse Reactions Caused by Obinutuzumab in the Treatment of Follicular Lymphoma [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 831-835.

[2]

ZHANG Yunhui, CHEN Haoyun, ZHONG Luhua, FANG Caifu, HUANG Huanjun, GUO Chenchen, DONG Xinyi, SHI Feng, LIANG Weiting. 159 Cases of Adverse Reactions to Immune Checkpoint Inhibitors [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 442-446.

[3]

[4]

[5]

ZENG Ji, ZHANG Jinke, WANG Li, CHEN Jun, MENG Xudong, NING Jing, HUANG Cheng. One Case of Rash Caused by Apalutamide Combined with Goserelin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 472-474.

[6]

BU Zixuan, XUE Mengwei, TIAN Jiawei, KE Kaile, WANG Ziying, LI Xiao, LU Tiangong. Interventions of Guizhi Fuling Pills in Properties of Ovarian Cancer Stem Cells [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 263-270.

[7]

LONG Minjuan, ZHAO Xu, GUO Longxin, CAI Yuhan, LIN Li, ZHU Shengkai, LIU Wenlong, SONG Haibo, XIAO Xiaohe. Big Data Analysis of Liver Adverse Reactions Monitoring of Chinese and Western Medicines Based on Age Correction and Risk Warning for Dermatologic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 271-275.

[8]

FAN Liping, LU Shu, CAI Yueping, WAN Yuxiang, SUN Huiyuan. Kanglaite Combined with Gefitinib for Mid-Late Stage Lung Cancer：a Meta-Analysis and Trial Sequential Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 316-323.

[9]

LIU Nannan, XI Yalin, CHEN Zhe. One Case of Adrenocortical Insufficiency Caused by Cadonilimab [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 109-112.

[10]

ZHANG Wei, XU Dongjie, JIN Yu, ZOU Ying, ZHANG Ting, ZHOU Jiancheng. One Case of Heart Failure Caused by Furmonertinib Mesilate Tablets [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 113-115.

[11]

WANG Hengxin, DUN Wenliang, HU Jinwen, LI Qing, ZHAO Zeyu, LUO Tianjiong. Identification and clinical characteristics of potential suspicious traditional Chinese medicines in traditional Chinese medicine-related liver injury [J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1130-1136.

[12]

CHEN Chunyan, TANG Yingjie, ZHAO Haixia, PAN Huimin, ZHU Qingmei. Ninety-seven cases of adverse drug reaction caused by urinary kininogenase for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1143-1147.

[13]

WANG Ying, HUANG Shan, SHENG Qinyong, LIAN Xia, CHANG Ying, JIANG Yan, LIN Bing, HUANG Aiwen. Seventy-nine cases of tislelizumab-related adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1148-1153.

[14]

GU Chenchen, ZONG Liuliu, YAO Yamin, SHEN Jie. Mining of adverse event signals of polatuzumab vedotin based on FAERS [J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1159-1165.

[15]

LIU Meng, FANG Ke, YAN Jiaju, LIU Meng, HE Manyun, WEI Liangbing. One case of anaphylactic shock caused by pamidronate disodium glucose injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1172-1174.

PDF (PC)

Knowledge